NNVC - NanoViricides, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc.

NNVC 2.120

+12.2%

2:17 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

drkaz

From: hpgrant

6/1/2015 1:47:59 PM

1 Recommendation Read Replies (2) of 12871

Did NNVC hire sister of board member for clinical work?

I just posted this on another board where it may have a brief lifespan:

leifsmith	Monday, 06/01/15 01:37:26 PM
Re: None
Post # of112126

Subject line: hired sister of board member for clinical work

Nanotoday just posted this:

Quote:NNVC hired the sister of one of its board members to do clinical work

Two facts cause me to doubt that this post had any purpose other than to deliberately mislead.

1) Dr. Milton Boniuk was appointed to the board of NNVC in May 2013
nanoviricides.com

2) Dr. Vivian Boniuk did the studies referred to before April 2009
businesswire.com

Therefore the claim that NNVC hired the sister of a board member is not true. It is true that Dr. Boniuk four years later did become a board member, and that part of the reason for it was his confidence in the work that had earlier been done by his sister.

Nanotoday also claimed the studies were paid for by NNVC. There is no evidence of that in the press release, raising the question: "What is the basis for the claim?":

Quote:WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that Dr. Vivien Boniuk, Associate Professor of Ophthalmology, Albert Einstein College of Medicine, associated with the North Shore Long Island Jewish Health System (NSLIJ), will be presenting additional results from the animal studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC). These studies were conducted at the Feinstein Institute for Medical Research of the NSLIJ. Dr. Boniuk will be speaking at the GTC-Bio Conference on Ocular Diseases and Drug Discovery on April 21 in Philadelphia, PA.

Nanotoday: Your post casts suspicion on the integrity of the company. If that was not your intention would you please take this opportunity to correct the implications of your post, and acknowledge that Dr. Milton Boniuk was not a member of the NNVC board at the time Dr. Vivian Boniuk did the work at the Feinstein Institute for Medical Research of the NSLIJ.

To leave this uncorrected will make it obvious to all readers of this board that your intention was to damage the reputation of the company.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next